Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia

Summary

The current study is an exploratory, phase IIa randomized clinical trial (RCT) aiming to evaluate if early presepsin increase coupled with early initiation of anakinra as an adjunct therapy to the standard-of-care treatment may improve outcomes of community-acquired pneumonia or hospital-acquired pneumonia.

Timeline

Start

2023-03-06

Primary completion

2024-06-28

Completion

2024-06-28

Publications

• Tavoulareas G, Kontakou-Zoniou O, Antonakos N, Tasouli E, Adamis G, Kakavoulis N, Michelakis E, Skopelitis I, Dakou K, Psarrakis C, Koufargyris P, Astriti M, Sympardi S, Giamarellos-Bourboulis EJ. Efficacy of anakinra in reducing progression to organ dysfunction in patients with pneumonia (INSPIRE): a randomised, double-blind, placebo-controlled, phase IIa trial. Lancet Reg Health Eur. 2025 Dec 29;62:101573. doi: 10.1016/j.lanepe.2025.101573. eCollection 2026 Mar.

Drugs

Indications